N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis
Open Access
- 22 July 2021
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 19 (1) , 1-14
Abstract
Background: Progressive multiple sclerosis (PMS) is an uncommon and severe subtype of MS that worsens gradually and leads to irreversible disabilities in young adults. Currently, there are no applicable or reliable biomarkers to distinguish PMS from relapsing–remitting multiple sclerosis (RRMS). Previous studies have demonstrated that dysfunction of N6-methyladenosine (m6A) RNA modification is relevant to many neurological disorders. Thus, the aim of this study was to explore the diagnostic biomarkers for PMS based on m6A regulatory genes in the cerebrospinal fluid (CSF). Methods: Gene expression matrices were downloaded from the ArrayExpress database. Then, we identified differentially expressed m6A regulatory genes between MS and non-MS patients. MS clusters were identified by consensus clustering analysis. Next, we analyzed the correlation between clusters and clinical characteristics. The random forest (RF) algorithm was applied to select key m6A-related genes. The support vector machine (SVM) was then used to construct a diagnostic gene signature. Receiver operating characteristic (ROC) curves were plotted to evaluate the accuracy of the diagnostic model. In addition, CSF samples from MS and non-MS patients were collected and used for external validation, as evaluated by an m6A RNA Methylation Quantification Kit and by real-time quantitative polymerase chain reaction. Results: The 13 central m6A RNA methylation regulators were all upregulated in MS patients when compared with non-MS patients. Consensus clustering analysis identified two clusters, both of which were significantly associated with MS subtypes. Next, we divided 61 MS patients into a training set (n = 41) and a test set (n = 20). The RF algorithm identified eight feature genes, and the SVM method was successfully applied to construct a diagnostic model. ROC curves revealed good performance. Finally, the analysis of 11 CSF samples demonstrated that RRMS samples exhibited significantly higher levels of m6A RNA methylation and higher gene expression levels of m6A-related genes than PMS samples. Conclusions: The dynamic modification of m6A RNA methylation is involved in the progression of MS and could potentially represent a novel CSF biomarker for diagnosing MS and distinguishing PMS from RRMS in the early stages of the disease.Keywords
Funding Information
- National Natural Science Foundation of China (81671132, 81471180, 82071286)
This publication has 43 references indexed in Scilit:
- Treatment of progressive multiple sclerosis: what works, what does not, and what is neededThe Lancet Neurology, 2015
- Inhibition of Hyaluronan Synthesis Protects against Central Nervous System (CNS) Autoimmunity and Increases CXCL12 Expression in the Inflamed CNSJournal of Biological Chemistry, 2014
- Epigenome-wide differences in pathology-free regions of multiple sclerosis–affected brainsNature Neuroscience, 2013
- The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitryNature Neuroscience, 2013
- Genetic Variants in the Fat and Obesity Associated (FTO) Gene and Risk of Alzheimer's DiseasePLOS ONE, 2012
- Cerebrospinal hepatocyte growth factor levels correlate negatively with disease activity in multiple sclerosisJournal of Neuroimmunology, 2012
- A commonly carried allele of the obesity-relatedFTOgene is associated with reduced brain volume in the healthy elderlyProceedings of the National Academy of Sciences, 2010
- Neurofilament light as a prognostic marker in multiple sclerosisMultiple Sclerosis Journal, 2010
- Primary-progressive multiple sclerosisThe Lancet Neurology, 2007
- Secondary progressive multiple sclerosis: current knowledge and future challengesThe Lancet Neurology, 2006